| Document |
Document Title |
|
WO/2020/063696A8 |
Provided are a preparation of a semicarbazide-sensitive amine oxidase inhibitor and the use thereof. In particular, dislosed are a compound as shown in formula I, or a stereoisomer or racemate or pharmaceutically acceptable salt thereof....
|
|
WO/2021/064073A1 |
Compounds of the formula (I) wherein the substituents are as defined in claim 1, useful as a pesticides, especially as herbicides.
|
|
WO/2021/059136A1 |
Compounds of the general formula (I), or a pharmaceutically acceptable salt thereof, processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.
|
|
WO/2021/055627A1 |
The invention provides substituted N-heterocyclic carboxamides and related compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat a medical disorder, e.g., cancer, ...
|
|
WO/2021/047581A1 |
Disclosed is a hexahydrobenzopyrazole compound shown in formula (I), and a stereoisomer, a pharmaceutically acceptable salt, a solvate, a hydrate, an N-oxide, a prodrug, and a pharmaceutical composition thereof, a preparation method ther...
|
|
WO/2021/046789A1 |
Disclosed are indazole-carboxamide derivatives and use thereof, specifically a class of indazole-carboxamide derivatives and pharmaceutical compositions containing such compounds, which can be used as 5-HT4 receptor agonists, a method fo...
|
|
WO/2021/023805A1 |
The present invention relates to a compound for treatment of a disease or disorder involving depression, erectile dysfunction, anxiety, sexual dysfunction and/or ejaculatory disorders; or a combination thereof.
|
|
WO/2020/219639A1 |
The invention provides compounds of formula (I): (I) or pharmaceutically-acceptable salts thereof, that are inhibitors of Janus kinases and release an active metabolite in vivo. The invention also provides pharmaceutical compositions com...
|
|
WO/2020/201991A1 |
Compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative diseases. Methods of using compounds of Formula I or a stereoi...
|
|
WO/2020/184670A1 |
The present invention relates to a method for monodeuterated lower alkylating an amine moiety of a compound which contains an amine that is protected by an aralkyl group, wherein a monodeuterated lower alkyl is introduced into the amine ...
|
|
WO/2020/160493A3 |
Provided herein are 8-methyl-8-azabicyclo[3.2.1]octan-3-yl and pyridin-4-ylmethanyl ester and amide compounds and compositions. Also provided herein are methods of preventing or delaying the onset of myopia in a subject in need thereof, ...
|
|
WO/2020/181283A1 |
The invention relates to carboxamide-pyrimidine derivatives of the general formula (I), or a pharmaceutically acceptable salt thereof, and the use of the compounds of the present invention for the treatment of hyperproliferative diseases...
|
|
WO/2020/157691A1 |
Provided herein are novel crystalline forms of a crystalline compound of Formula (I), which modulates the ORL-1 receptor. The crystalline compounds of Formula (I), compositions thereof, and methods of using thereof that are described her...
|
|
WO/2020/156241A1 |
The present invention relates to aromatic ring or heteroaromatic ring compounds, a preparation method therefor and a medical use thereof. Particularly, the present invention relates to a compound as shown in general formula (I) and a pre...
|
|
WO/2020/150385A1 |
The invention is directed to compounds that are active as antibacterial agents. The invention compounds are active against gram-positive and gram-negative bacteria and can be used to treat infections caused by gram-positive and gram-nega...
|
|
WO/2020/150372A1 |
The invention is directed to compounds that are active as antibacterial agents. The invention compounds are active against gram-positive and gram-negative bacteria and can be used to treat infections caused by gram-positive and gram-nega...
|
|
WO/2020/142503A1 |
In alternative embodiments, the provided are therapeutic combinations comprising: nucleophilic hydroxyimino-acetamido alkylamine antidotes that cross the blood-brain barrier (BBB) to catalyze the hydrolysis of organophosphate (OP)-inhibi...
|
|
WO/2020/135210A1 |
Disclosed are a substituted aryl compound or pharmaceutically acceptable salts thereof, a stereoisomer, a polymorphic substance, a solvate, a N-oxide, an isotopically labeled compound, a metabolite or a prodrug and a preparation method t...
|
|
WO/2020/115505A1 |
This invention relates to compounds that are agonists of the muscarinic M1 and/or M4 receptor and which are useful in the treatment of diseases mediated by the muscarinic M1 and M4 receptors. Also provided are pharmaceutical compositions...
|
|
WO/2020/115506A1 |
This invention relates to compounds having activity as muscarinic M1 or M1 and M4 receptor agonists which are useful in the treatment of diseases mediated by the muscarinic M1 and M4 receptors. Also provided are pharmaceutical compositio...
|
|
WO/2020/108516A1 |
Disclosed are a nitrogen-containing heteroaryl derivative compound as shown in the general formula (I), a preparation method thereof, and a pharmaceutical composition containing the same. The compound can be used as a JAK inhibitor and c...
|
|
WO/2020/108613A1 |
The present invention relates to heteroaromatic derivatives for use as a regulator, a preparation method therefor and a use thereof. In particular, disclosed are compounds represented by general formula (I), preparation methods therefor,...
|
|
WO/2020/097635A1 |
The invention provides an improved method for the production of Scopolamine by extraction.
|
|
WO/2020/063696A1 |
Provided are a preparation of amine urea sensitive amine oxidase inhibitor and the use thereof. In particular, dislosed are a compound as shown in formula I, or a stereoisomer or racemate or pharmaceutically acceptable salt thereof. Also...
|
|
WO/2020/063320A1 |
The application provides a method for improving the stability of a low-concentration atropine ophthalmic preparation, as well as a method for preparing the ophthalmic preparation, an atropine ophthalmic preparation prepared thereby and a...
|
|
WO/2020/047312A1 |
This invention is directed to heteroaryl-substituted sulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of di...
|
|
WO/2020/035464A1 |
The present invention relates to compounds of formula (I): wherein Q is selected from O or S; R1 and R3 are each independently hydrogen or an optionally substituted hydrocarbyl group, or R1 and R3 together with the nitrogen atom to which...
|
|
WO/2020/027723A1 |
The present disclosure relates to derivatives of bicyclic compounds and their uses in therapy. In particular, the present disclosure relates to derivatives of bicyclic compounds for use in modulating kinase enzymatic activity and accordi...
|
|
WO/2020/022323A1 |
A compound of formula (I):wherein Ring A, Q, R1,R2, R3, R4, R5, R6, R7, R8, R9, R10, R11,X, a,b, c and d are as defined in the specification.
|
|
WO/2020/012427A1 |
The present invention relates to compounds of Formula (Ia) or pharmaceutically acceptable salts, hydrates, solvates, clathrates, polymorphs, stereoisomers thereof. It further discloses a pharmaceutical composition comprising the compound...
|
|
WO/2020/006296A1 |
The present invention is directed towards compounds having the Formula (lb) or the Formulae (III) and pharmaceutically acceptable salts, solvates and clathrates thereof, compositions thereof, as well as towards the use of said compounds ...
|
|
WO/2019/243414A1 |
The present invention relates to soluble epoxide hydrolase (sEH) inhibitors of formula (I) to processes for their obtention and to their therapeutic indications.
|
|
WO/2019/243850A1 |
This invention relates to compounds that are agonists of the muscarinic M1 and/or M4 receptor and which are useful in the treatment of diseases mediated by the muscarinic M1 and M4 receptors. Also provided are pharmaceutical compositions...
|
|
WO/2019/241292A1 |
Described herein are hepatitis B capsid assembly modulators and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of hepatitis B.
|
|
WO/2019/226490A1 |
Provided is a compound of Formula (I), wherein the variable groups are defined herein.
|
|
WO/2019/214656A1 |
A fluorine-containing isoxazole compound, a preparation method therefor, and a pharmaceutical composition and use thereof. Specifically, disclosed is a compound represented by general formula I or enantiomers or diastereoisomers thereof,...
|
|
WO/2019/210879A1 |
The present invention relates to a bicyclic nucleocapsid inhibitor and use thereof as a drug for treating hepatitis B. Specifically, disclosed is a compound which can be used as an HBV inhibitor and has a structure represented by chemica...
|
|
WO/2019/212937A1 |
The present invention relates to pyridazinones and related compounds of Formula I which are inhibitors of PARP7 and are useful in the treatment of cancer.
|
|
WO/2019/199972A1 |
Described herein are splice modifying compounds affecting splicing of mRNA, such as pre-mRNA, expressed from the FOXM1 gene, compositions comprising thereof, and methods using the same.
|
|
WO/2019/189555A1 |
Provided is a compound that can have a CDK12-inhibiting effect and that is expected to be useful as a preventive or therapeutic drug for cancer and the like. The compound or salt thereof is represented by formula (I) (where each symbol i...
|
|
WO/2019/126253A8 |
Disclosed are compounds of Formula (I) or salts thereof, wherein A, G, R1, R5, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmace...
|
|
WO/2019/143508A1 |
Efficient methods are provided for large scale production of ethyl cocaine-free cocaine hydrochloride. Compositions and methods comprising administration of cocaine hydrochloride are provided.
|
|
WO/2019/141096A1 |
Provided is a substituted urea compound, and a preparation method and use thereof. More particularly, the invention relates to a substituted urea compound or a pharmaceutically acceptable salt, a stereoisomer, a polymorphic substance, a ...
|
|
WO/2019/126253A1 |
Disclosed are compounds of Formula (I) or salts thereof, wherein A, G, R1, R5, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmace...
|
|
WO/2019/110521A1 |
The present invention relates to fluorophenyl substituted muscarinic receptor ligands with selectivity for M3 over M2 and to the use of these compounds in the treatment of various diseases such as asthma, chronic obstructive pulmonary di...
|
|
WO/2019/104011A1 |
Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with the en...
|
|
WO/2019/099307A1 |
The present technology is directed to compounds, compositions, and methods related to inhibition of ASK1. In particular, the present compounds (e.g., compounds of Formula I as defined herein) and compositions may be used to treat ASK1-me...
|
|
WO/2019/084383A1 |
The invention provides a compound of formula (I): (Formula (I)) or a pharmaceutically-acceptable salt thereof, that is an inhibitor of JAK kinases. The invention also provides pharmaceutical compositions comprising such compound, a cryst...
|
|
WO/2019/079626A1 |
Isoquinoline compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an isoquinoline compound or analogs thereof, in the treatment of disorders characterized by...
|
|
WO/2019/040106A3 |
The present disclosure relates to compounds according to Formulae disclosed herein, useful for treating diseases.
|
